KR20080017482A - 5-ｈｔ6-수용체 저해제로서의 벤조퓨라닐 유도체 - Google Patents

5-ｈｔ6-수용체 저해제로서의 벤조퓨라닐 유도체 Download PDF

Info

Publication number
KR20080017482A
KR20080017482A KR1020087001242A KR20087001242A KR20080017482A KR 20080017482 A KR20080017482 A KR 20080017482A KR 1020087001242 A KR1020087001242 A KR 1020087001242A KR 20087001242 A KR20087001242 A KR 20087001242A KR 20080017482 A KR20080017482 A KR 20080017482A
Authority
KR
South Korea
Prior art keywords
compound
treatment
nervous system
central nervous
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087001242A
Other languages
English (en)
Korean (ko)
Inventor
파트리치아 칼디롤라
가뤼 요한손
로리 서틴
Original Assignee
바이오비트럼 에이비(피유비엘)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오비트럼 에이비(피유비엘) filed Critical 바이오비트럼 에이비(피유비엘)
Publication of KR20080017482A publication Critical patent/KR20080017482A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020087001242A 2005-06-17 2006-06-15 5-ｈｔ6-수용체 저해제로서의 벤조퓨라닐 유도체 Ceased KR20080017482A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0501383 2005-06-17
SE0501383-4 2005-06-17
US70652305P 2005-08-09 2005-08-09
US60/706,523 2005-08-09

Publications (1)

Publication Number Publication Date
KR20080017482A true KR20080017482A (ko) 2008-02-26

Family

ID=36659956

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087001242A Ceased KR20080017482A (ko) 2005-06-17 2006-06-15 5-ｈｔ6-수용체 저해제로서의 벤조퓨라닐 유도체

Country Status (18)

Country Link
US (1) US7582767B2 (https=)
EP (1) EP1896460B1 (https=)
JP (1) JP2008543813A (https=)
KR (1) KR20080017482A (https=)
CN (1) CN101193885B (https=)
AU (1) AU2006259082B2 (https=)
BR (1) BRPI0612746A2 (https=)
CA (1) CA2610383A1 (https=)
DE (1) DE602006008002D1 (https=)
DK (1) DK1896460T3 (https=)
EA (1) EA015671B1 (https=)
ES (1) ES2330145T3 (https=)
IL (1) IL187575A (https=)
MX (1) MX2007015988A (https=)
NO (1) NO20080354L (https=)
NZ (1) NZ563510A (https=)
WO (1) WO2006134150A1 (https=)
ZA (1) ZA200710468B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0303480D0 (sv) * 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
CN103880797B (zh) * 2014-03-26 2015-12-02 沈阳大学 苯并呋喃类化合物及其医药用途
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
EP3955920A1 (en) 2019-04-16 2022-02-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
CA2353962C (en) 1998-12-11 2009-09-29 Virginia Commonwealth University Selective 5-ht6 receptor ligands
CN1800185A (zh) 2001-06-11 2006-07-12 比奥维特罗姆股份公司 取代的磺酰胺化合物、其制备方法及其作为治疗cns疾病、肥胖和ii型糖尿病的药物的应用
RS44204A (sr) * 2001-11-22 2007-06-04 Biovitrum Ab., Inhibitori 11-beta- hidroksistereoidne dehidrogenaze tipa 1
WO2004000828A1 (en) 2002-06-20 2003-12-31 Biovitrum Ab New compounds useful for the treatment of obesity, type ii diabetes and cns disorders
JP4754821B2 (ja) * 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
SE0303480D0 (sv) * 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes

Also Published As

Publication number Publication date
EP1896460A1 (en) 2008-03-12
WO2006134150A1 (en) 2006-12-21
DE602006008002D1 (de) 2009-09-03
IL187575A0 (en) 2008-03-20
MX2007015988A (es) 2008-03-07
JP2008543813A (ja) 2008-12-04
US20060293361A1 (en) 2006-12-28
US7582767B2 (en) 2009-09-01
CN101193885A (zh) 2008-06-04
AU2006259082A1 (en) 2006-12-21
AU2006259082B2 (en) 2011-07-14
NZ563510A (en) 2011-01-28
BRPI0612746A2 (pt) 2010-11-30
ES2330145T3 (es) 2009-12-04
EA015671B1 (ru) 2011-10-31
IL187575A (en) 2012-12-31
EP1896460B1 (en) 2009-07-22
CN101193885B (zh) 2011-07-27
ZA200710468B (en) 2009-04-29
CA2610383A1 (en) 2006-12-21
HK1112918A1 (en) 2008-09-19
DK1896460T3 (da) 2009-11-16
EA200800071A1 (ru) 2008-10-30
NO20080354L (no) 2008-01-17

Similar Documents

Publication Publication Date Title
JP6714673B2 (ja) シクロアルキルカルボキサミド−インドール化合物の製造方法
US20060148818A1 (en) Novel tetraydrospiro(piperdine-2,7'- pyrrolo{3,2-b}pyridine derivatives and novel in-dole derivatives useful in the treatment of 5-ht6 receptor-related disorders
US20060142269A1 (en) New compounds
Seggel et al. A structure-affinity study of the binding of 4-substituted analogs of 1-(2, 5-dimethoxyphenyl)-2-aminopropane at 5-HT2 serotonin receptors
HUE032540T2 (en) Modulators of ATP-binding cassette transporters
CN105693701A (zh) Atp-结合盒转运蛋白的调节剂
EP2567698A1 (en) GPR 17 agonists and screening assay
JP2018519253A (ja) Ｇｐｒ５２に関連する障害の治療または予防に有用なｇｐｒ５２のモジュレーターとしての１−ヘテロアリール−インドリン−４−カルボキサミド
KR20080017482A (ko) 5-ｈｔ6-수용체 저해제로서의 벤조퓨라닐 유도체
Cai et al. Design, synthesis, and biological evaluation of benzofuran derivatives as ET receptor antagonists
Matassa et al. Synthesis and in vitro LTD4 antagonist activity of bicyclic and monocyclic cyclopentylurethane and cyclopentylacetamide N-arylsulfonyl amides
TW568786B (en) A combination, pharmaceutical formulation, and kit for use in the treatment of affective disorders
HK1112918B (en) Benzofuranyl derivatives as 5-ht6-receptor inhibitors
WO2006062481A1 (en) New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
JP2003519229A (ja) 新規ヘテロアリール誘導体、その製造方法及びその使用方法
CN120230097A (zh) 一类吲哚衍生物、其制备方法、药物组合物及其应用
CN108129465A (zh) 一种2-吡嗪衍生物取代的咪唑类化合物及其在防治骨质疏松药物中的应用
KR20070020373A (ko) 5-ＨＴ6 수용체-관련 장애의 치료에 유용한 신규한 테트라히드로스피로｛피페리딘-2,7'-피롤로[3,2-ｂ]피리딘｝ 유도체 및 신규한 인돌 유도체
ZA200602756B (en) Novel tetraydrospiro{piperidine-2,7'-pyrrolo[3,2-b]pyridine derivatives and novel indole derivatives useful in the treatment of 5-HT6 receptor-related disorders
CN109280037A (zh) 3-氰基苯氧烷基芳基哌嗪衍生物及在制备药物中的应用
EP1897876A2 (en) Compounds useful for the treatment of obesity, type II diabetes and CNS disorders
HK1261194A1 (en) Intermediate compound for process of producing cycloalkylcarboxamido-indole compounds
HK1261194B (en) Intermediate compound for process of producing cycloalkylcarboxamido-indole compounds
JP2008189620A (ja) 甲状腺ホルモン受容体アンタゴニスト及び医薬
CN102512413A (zh) 2-烷基-苯并咪唑-1-乙酰腙及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080116

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110613

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20121109

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130530

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20121109

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I